:Study Objective(s):Pharmacogenomics (PGx) testing, in particular combinatorial PGx testing, represents a potential means for delivering personalized treatment selection for patients with psychiatric disorders. The goal of this educational intervention was to educate clinicians about the role of PGx testing in neuropsychiatric conditions such as MDD, how these novel tests may be implemented into clinical practice, and how results may be used to inform decision-making.Method:Psychiatrists (n=830) participated in an online enduring CME activity on PGx testing in psychiatric disorders •The format was a 30-minute 2-person discussion (launched December 7, 2018)•Data from this activity were collected for 30 days after launch•Effectiveness of education for the CME activities was analyzed using 3 multiple-choice and 1 self-efficacy question (5-point Likert-type scale), presented as pre-/post-CME repeated pairs•A paired samples t-test was conducted to examine improvements in mean confidence pre and postParticipant knowledge, competence, and confidence change in pre- to post-CME responses were calculatedResults:Overall, 72% of psychiatrists (n=830) had knowledge or competence that was reinforced or improved as a result of education.Following education:*56% and 12% of psychiatrists had reinforcement and improvement, respectively, in knowledge related to the clinical benefits of PGx-guided treatment strategies•61% and 8% of psychiatrists had reinforcement and improvement, respectively, in competence related to interpreting PGx tests for patients with neuropsychiatric disorders•Within the group of psychiatrists with reinforced and improved knowledge/competence, there was a 30% increase in their confidence using PGx tests to help guide treatment decisions for patients with major depressive disorder (MDD) (M pre=2.14, post=2.77, scale 1 to 5)•Confidence in the use of PGx testing was correlated with likelihood of considering PGx testing for patients with MDDConclusions:Online CME aided in psychiatrists’ knowledge, competence, and confidence in using pharmacogenomics testing in patients with psychiatric disorders.Funding Acknowledgements:Supported by an independent educational grant from Myriad Neuroscience, formerly Assurex Health

中文翻译：

---

137 CME 药物基因组学测试提高了与在实践中实施测试相关的知识、能力和信心

：研究目标：药物基因组学 (PGx) 测试，特别是组合 PGx 测试，代表了为精神疾病患者提供个性化治疗选择的潜在手段。这种教育干预的目的是让临床医生了解 PGx 测试在神经精神疾病（如 MDD）中的作用，这些新测试如何在临床实践中实施，以及如何将结果用于为决策制定提供信息。方法：精神科医生（ n=830) 参加了一项关于精神疾病 PGx 测试的在线持久 CME 活动•形式为 30 分钟的 2 人讨论（2018 年 12 月 7 日推出）•此活动的数据是在发布后 30 天内收集的•使用 3 个多项选择和 1 个自我效能问题（李克特 5 点量表）分析 CME 活动的教育效果，以 CME 前后重复对的形式呈现•进行配对样本 t 检验以检查平均置信度前后的改进计算参与者在 CME 前后反应中的知识、能力和信心变化结果：总体而言，72% 的精神病医生 (n=830) 的知识或能力因教育而得到加强或提高。接受教育：*分别有 56% 和 12% 的精神科医生在与 PGx 指导的治疗策略的临床益处相关的知识方面得到了强化和改善•分别有 61% 和 8% 的精神科医生在解释神经精神疾病患者的 PGx 测试相关的能力方面得到了强化和改善•在知识/能力得到加强和提高的精神科医生群体中，他们使用 PGx 测试来帮助指导重度抑郁症 (MDD) 患者的治疗决策的信心增加了 30%（M pre=2.14，post=2.77，规模1 至 5)•使用 PGx 检测的信心与考虑对 MDD 患者进行 PGx 检测的可能性相关结论：在线 CME 有助于提高精神科医生在精神疾病患者中使用药物基因组学测试的知识、能力和信心。资金致谢：由 Myriad Neuroscience（前身为 Assurex Health）的独立教育资助提供支持